Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

Autor: Heerspink, H. J.L., Stefansson, B., Chertow, G., Correa-Rotter, R., Greene, Tom, Hou, Fan Fan, Lindberg, Magnus, McMurray, John, Rossing, P., Toto, Roberto, Langkilde, Anna Maria, Wheeler, David C., Wheeler, D. C., Greene, T., Hou, F. F., McMurray, J., Toto, R., Langkilde, A. M., Pfeffer, Marc A., Pocock, Stuart, Swedberg, Karl, Rouleau, Jean L., Chaturvedi, Nishi, Ivanovich, Peter, Levey, Andrew S., Christ-Schmidt, Heidi, Mann, Johannes, Held, Claes, Varenhorst, Christoph, Holmgren, Pernilla, Hallberg, Theresa, Douthat, Walter, Filho, Roberto Pecoits, Cherney, David, Persson, Frederik, Haller, Hermann, Wittmann, István, Khullar, Dinesh, Naoki, Kashihara, Correa-Rotter, Richardo, Escudero, Elizabeth, Isidto, Rey, Nowicki, Michal, Batiushin, Mikhail

Publikováno v: Nephrology Dialysis Transplantation
Nephrology Dialysis Transplantation, 35(2), 274-282. Oxford University Press
Heerspink, H J L, Stefansson, B, Chertow, G, Correa-Rotter, R, Greene, T, Hou, F F, Lindberg, M, McMurray, J, Rossing, P, Toto, R, Langkilde, A M, Wheeler, D C, Heerspink, H J L, Wheeler, D C, Chertow, G, Correa-Rotter, R, Greene, T, Hou, F F, McMurray, J, Rossing, P, Toto, R, Stefansson, B, Langkilde, A M, Pfeffer, M A, Pocock, S, Swedberg, K, Rouleau, J L, Chaturvedi, N, Ivanovich, P, Levey, A S, Christ-Schmidt, H, Mann, J, Held, C, Varenhorst, C, Holmgren, P, Hallberg, T, Douthat, W, Filho, R P, Cherney, D, Hou, F F, Persson, F, Haller, H, Wittmann, I, Khullar, D, Naoki, K, Correa-Rotter, R, Escudero, E, Isidto, R, Nowicki, M, Batiushin, M & DAPA-CKD Investigators 2020, ' Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial ', Nephrology Dialysis Transplantation, vol. 35, no. 2, pp. 274-282 . https://doi.org/10.1093/ndt/gfz290

Background Recent cardiovascular outcome trials have shown that sodium–glucose co-transporter 2 (SGLT2) inhibitors slow the progression of chronic kidney disease (CKD) in patients with type 2 diabetes at high cardiovascular risk. Whether these bene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d7ee7be4cfa9b1001a569aca9821c18
https://doi.org/10.1093/ndt/gfz290

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial

Autor: Neuen B, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, Cannon C, Charytan D, Edwards R, Gorriz J, Jardine M, Levin A, Neal B, De Nicola L, Pollock C, Rosenthal N, Wheeler D, Mahaffey K, Heerspink H

Publikováno v: EUROPEAN HEART JOURNAL
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname

AIMS: Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal use of agents that block the renin-angiotensin-aldosterone system, particularly in patients with chronic kidney disease (CKD). In patients with CKD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::c00bbe768174fce5c9a30ed495009d98
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15911

TIRZEPATIDE REDUCES ALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES: POST HOC POOLED ANALYSIS OF SURPASS-1 to -5

Autor: Heerspink, H., Tuttle, K., Pavo, I., Haupt, A., Yang, Z., Wiese, R., Hemmingway, A., Cherney, D., Sattar, N., Longuet, C.

Publikováno v: In Canadian Journal of Diabetes November 2023 47(7) Supplement:S114-S114